In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.

Read the full coverage here:

Blue-collar workers more likely to miss work, quit due to psoriatic arthritis

Infliximab biosimilar uptake rapidly increased only after release of a third option

National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala

Safety checklist compiles clinically important DMARD warnings in one place

Guselkumab demonstrates long-term efficacy, safety in psoriasis

References:

Colla N, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-07077-1.

Gargiulo L, et al. J Drugs Dermatol. 2024;doi:10.36849/JDD.7486R1.

Press Release

Roberts ET, et al. Arthritis Rheumatol. 2024;doi:10.1002/art.42963.

Skaarup L, et al. Drug Saf. 2024;doi:10.1007/s40264-024-01461-1.

In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more.

Read the full coverage here:

FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy

Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’

Perioperative nivolumab improves outcomes in resectable NSCLC

Despite progress, barriers to lung cancer biomarker testing persist

Atezolizumab regimen ‘merits further study’ for unresectable NSCLC

References:

Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Press Release

Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897.

Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

In this edition, enrollment and dosing complete in phase 1 trial of AIV007, popular benchmarks in clinical practice guidelines and more.

Read the full coverage here:

Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema

OCT, visual acuity popular benchmarks in clinical practice guidelines for DME

First patient dosed in phase 2 trial of EC-104 implant for diabetic macular edema

OCS-01 eye drop for DME in second stage of phase 3 trial

Q&A: Susvimo delivers immediate durability after implantation in wet AMD

References:

Crawford C. Update on OCS-01: A novel topical drop for DME in phase 3 trials. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Healio Interviews

McAllister M, et al. Assessing the strength of clinical practice guidelines for managing diabetic macular edema — A systematic literature review. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

Press Release

Press Release

In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more.

Read the full coverage here:

Enbrel, Stelara to be discounted nearly 70% through Medicare price negotiations

Opioid use has fallen 15% annually since 2014 in autoimmune rheumatic disease

Inhibitor class PsO treatments exhibit similar efficacy in mitigating PsA risk

S100 protein levels predict abatacept response in juvenile idiopathic arthritis

Izokibep shows early promise in hidradenitis suppurativa

References:

Brunner HI, et al. Arthritis Res Ther. 2024;doi:10.1186/s13075-024-03347-0.

Falasinnu T, et al. Lancet Rheumatol. 2024;doi:10.1016/S2665-9913(24)00120-6.

Press Release

Press Release

Tsai SHL, et al. J Am Acad Dermatol. 2024;doi:10.1016/j.jaad.2024.07.1473.

In this edition, low education level raises follow-up risk in screening program, screening judgement strongly influenced by clinicians and more.

Read the full coverage here:

Low education level raises risk for loss to follow-up in lung cancer screening program

Lung cancer screening judgement strongly influenced by clinicians

Occupational benzene exposure heightens lung cancer likelihood

Chemotherapy plus nintedanib has ‘promising’ efficacy in small cell lung cancer with IPF

Blood biomarker identifying benign lung nodules performs well across subgroups

References:

Ikeda S, et al. Ann Am Thorac Soc. 2024;doi:10.1513/AnnalsATS.202311-941OC.

Long KJ, et al. CHEST. 2023;doi:10.1016/j.chest.2023.06.037.

Mugutso E, et al. Ann Am Thorac Soc. 2023;doi:10.1513/AnnalsATS.202304-348RL.

Núñez ER, et al. Am J Respir Crit Care Med. 2024;doi:10.1164/rccm.202301-0155OC.

Wan W, et al. Am J Respir Crit Care Med. 2024;doi:10.1164/rccm.202306-0942OC.

In this edition, sozinibercept combination therapy shows durability, comparable improvements with aflibercept and more.

Read the full coverage here:

Sozinibercept combination therapy shows durability in patients with DME, neovascular AMD

VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME

DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema

Eluminex doses first patient in phase 1b trial of EB-105 for diabetic macular edema

VIDEO: Port delivery system maintains visual, anatomic improvements in DME at 2 years

References:

Awh C. Port delivery system with ranibizumab for continuous treatment of diabetic macular edema: First readout of the phase 3 Pagoda trial year 2 results. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

Do D. Outcomes of patients with DME and baseline BCVA of 20/50 or worse or 20/40 or better treated with aflibercept 8 mg and 2 mg in the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

Phu A, et al. J Diabetes Complications. 2024;doi:10.1016/j.jdiacomp.2024.108808.

Press Release

Steinle NC. Durability of combination therapy of sozinibercept (OPT-302), an anti-VEGF-C/-D ‘trap’ with ranibizumab in nAMD or aflibercept in DME. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more.

Read the full coverage here:

Guselkumab brings active psoriatic arthritis into ‘stringent’ control through 2 years

Nearly one-quarter of all SARDs outpatient visits in US result in opioid prescription

FDA approves biosimilar Pyzchiva for all approved Stelara indications

Tofacitinib effective for juvenile idiopathic arthritis through 4 years

Bimekizumab results in rapid, sustained improvements to PsA patient reported outcomes

References:

Brunner HI, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2023-225094.

Gossec L, et al. Rheumatology. 2024;doi:10.1093/rheumatology/keae277.

Huang Y, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25378.

Press Release

Ritchlin CT, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06991-8.

In this edition, atezolizumab benefits PD-L1-selected patients with NSCLC, risks persist with e-cigarette use after quitting tobacco smoking and more.

Read the full coverage here:

Adjuvant atezolizumab benefits PD-L1-selected patients with NSCLC

Lung cancer risks persist with e-cigarette use after quitting tobacco smoking

COPD, IPF end of life health care use differs from lung cancer

Tecentriq combination fails to improve survival in metastatic lung cancer

Risk for lung cancer reoccurrence may be associated with OSA-related hypoxemia

References:

Figueroa Rodriguez F, et al. 0468: CRASH: Cancer reoccurrence is accelerated by episodic hypoxemia. Presented at: SLEEP; June 1-5, 2024; Houston.

Kim Y, et al. Association of electronic cigarette use after conventional smoking cessation with lung cancer risk: A nationwide cohort study. Presented at: American Thoracic Society International Conference; May 18-22, 2024; San Diego.

Press Release

Suen AO, et al. Am J Respir Crit Care Med. 2024;doi:10.1154/ajrccm-conference.2024.209.1_MeetingAbstracts.A5040.

Wakelee HA, et al. Abstract LBA8035. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.